In this in vivo context, the two IDH1 KO clones showed a significant delay in tumour growth and a longer time required to reach the xenograft study's endpoint compared to control cells (Fig. 5I,J), with loss of IDH1 leading to increased survival. Here, IDH1 is linked to neoplasm.